PT - JOURNAL ARTICLE AU - Barouch, Dan H. AU - Stephenson, Kathryn E. AU - Sadoff, Jerald AU - Yu, Jingyou AU - Chang, Aiquan AU - Gebre, Makda AU - McMahan, Katherine AU - Liu, Jinyan AU - Chandrashekar, Abishek AU - Patel, Shivani AU - Gars, Mathieu Le AU - de Groot, Anne Marit AU - Heerwegh, Dirk AU - Struyf, Frank AU - Douoguih, Macaya AU - van Hoof, Johan AU - Schuitemaker, Hanneke TI - Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19 AID - 10.1101/2021.07.05.21259918 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.05.21259918 4099 - http://medrxiv.org/content/early/2021/07/07/2021.07.05.21259918.short 4100 - http://medrxiv.org/content/early/2021/07/07/2021.07.05.21259918.full AB - Interim immunogenicity and efficacy data for the Ad26.COV2.S vaccine for COVID-19 have recently been reported1-3. We describe here the 8-month durability of humoral and cellular immune responses in 20 individuals who received one or two doses of 5×1010 vp or 1011 vp Ad26.COV2.S and in 5 participants who received placebo2. We evaluated antibody and T cell responses on day 239, which was 8 months after the single-shot vaccine regimen (N=10) or 6 months after the two-shot vaccine regimen (N=10), although the present study was not powered to compare these regimens3. We also report neutralizing antibody responses against the parental SARS-CoV-2 WA1/2020 strain as well as against the SARS-CoV-2 variants D614G, B.1.1.7 (alpha), B.1.617.1 (kappa), B.1.617.2 (delta), P.1 (gamma), B.1.429 (epsilon), and B.1.351 (beta).Competing Interest StatementD.H.B. is a co-inventor on related vaccine patents. J.S., M.L.G., A.M.G., D.H., F.S., M.D., J.V.H., and H.S. are employees of Janssen Pharmaceuticals and may be co-inventors on related vaccine patents.Clinical TrialNCT04436276Funding StatementWe acknowledge support from Janssen Vaccines & Prevention BV, the Ragon Institute of MGH, MIT, the Massachusetts Consortium on Pathogen Readiness (MassCPR), the Musk Foundation, the National Institutes of Health (CA260476). This project has been funded in part with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Other Transaction Agreement HHSO100201700018C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:BIDMC IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for access to the study data can be submitted to D.H.B. (dbarouch{at}bidmc.harvard.edu).